The effect of efavaleukin α, an IL-2 mutein Fc fusion protein with a high affinity to CD25, is also intensively investigated in SLE: in a phase 1b trial, different doses of efavaleukin had a tolerable safety profile while causing a selective and prolonged regulatory T cell expansion (86). Here, IL2 is linked to systemic lupus erythematosus.